Skip to content

Rectus Abdominis Detrusor Myoplasty for Urinary Retention

To Investigate the Outcomes of Rectus Abdominis Flap Detrusor Myoplasty for Urinary Retention

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07379814
Acronym
RADM
Enrollment
50
Registered
2026-01-30
Start date
2026-05-01
Completion date
2036-05-01
Last updated
2026-07-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Urinary Retention, Urinary Retention After Procedure, Urinary Retention Postoperative

Keywords

urinary retention

Brief summary

This investigates the outcomes of a surgical technique using the patient's own abdominal wall muscles to help contract the bladder in patients with urinary retention

Detailed description

This study is about a surgery called Rectus Abdominis Detrusor Myoplasty (RADM). In this surgery, a small piece of the belly muscle is moved and wrapped around your bladder to help it squeeze and empty urine. Doctors are studying this surgery because current treatments, like catheters or nerve implants, don't always work for people whose bladders don't contract on their own. This study monitors the patients' progress for a year following this surgery.

Interventions

PROCEDURERectus Abdominal Detrusor Myoplasty

In this surgery, the rectus abdominis muscle will be elevated and wrapped circumferentially around the bladder to augment bladder contraction in individuals with bladder acontractility or hypocontractility.

Sponsors

University Hospitals Cleveland Medical Center
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Hypo- or acontractility of the bladder documented on urodynamic testing * Injury \>1 year ago for spinal cord injury patients, no improvement in contractility with time * Failed sacral nerve stimulation implant for urinary retention treatment (If previously implanted) * Irreversible non-neurogenic bladder acontractility/hypocontractility (i.e myogenic failure after chronic obstruction, aging, frailty, idiopathic) * Undergoing RADM

Exclusion criteria

* Documented bladder outlet obstruction * Spinal cord lesion above T12 * Upper motor neuron lesion (i.e. multiple sclerosis, stroke) * Rectus diastasis, significant abdominal wall hernia, or other anatomic barrier to rectus flap harvest * Life expectancy \<10 years * Pregnant at time of surgery

Design outcomes

Primary

MeasureTime frameDescription
Change in Bladder Compliance6 Months and 1 Year Post-OpBladder compliance will be calculated as the change in bladder volume divided by the change in detrusor pressure during the filling phase and reported in milliliters per centimeter of water (mL/cm H₂O).
Change in Detrusor Pressure6 Months and 1 Year Post-OpDetrusor pressure during filling and voiding, including detrusor pressure at maximum flow, will be reported in centimeters of water (cm H₂O).
Change in presence of Detrusor Overactivity6 Months and 1 Year Post-OpDetrusor overactivity will be recorded as a binary variable (present or absent) based on the occurrence of involuntary detrusor contractions during filling.
Change in Urinary Flow Rate6 Months and 1 Year Post-OpMaximum urinary flow rate will be reported in milliliters per second (mL/s).
Change In Post-Void Residual Urine Volume in Urine6 Months and 1 Year Post-OpPost-void residual volume will be measured immediately following voiding and reported in milliliters (mL).

Secondary

MeasureTime frameDescription
Change in quality of life as measured by the Short-Form 36 (SF-36)Month 6 and Year 1 Post-OpThis is a validated questionnaire measuring health-related quality of life through eight domains, covering physical and mental well-being. It's widely used in healthcare to assess overall health perception and functional status. With higher scores indicating greater quality of life.

Countries

United States

Contacts

CONTACTSeyed Sajjad Tabei
seyedsajjad.tabei@uhhospitals.org216-844-8963
PRINCIPAL_INVESTIGATORShubham Gupta, MD

University Hospitals Cleveland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 7, 2026